DR. SURENDER K. SHARAWAT (PhD)  

401, 4^TH FLOOR, DR.B.R. AMBEDKAR IRCH
ALL INDIA INSTITUTE OF MEDICAL SCIENCES

ANSARI NAGAR, NEW DELHI, 110029
PHONE: +91 11 29575401 ;sk यह ईमेल पता spambots से संरक्षित किया जा रहा है. आप जावास्क्रिप्ट यह देखने के सक्षम होना चाहिए. , यह ईमेल पता spambots से संरक्षित किया जा रहा है. आप जावास्क्रिप्ट यह देखने के सक्षम होना चाहिए.

 

Educational Qualifications:

Degree	Institute	Specialization	Month/Year
Doctorate of Philosophy (PhD)	All India Institute of Medical Sciences, New Delhi, INDIA	Clinical Cancer Research	December, 2012
Master of Science	M.D. University, Haryana, INDIA	Biotechnology	September 2004
Bachelor of Science	M.D. University, Haryana, INDIA	Life Sciences	June 2002

 

Professional Experience:

 

Designation	Institute	Area of Working	Month/Year
Scientist-I	All India Institute of Medical Oncology New Delhi	Cancer Research	August 2016-Till date
Post-Doctoral Research Associates	National Institute of Immunology, New Delhi, INDIA	Cancer Stem cell biology	August 2015- January 2016
Post-Doctoral Research Associates	College of Medicine, University of Nebraska Medical Center, Omaha, USA	Stem Cell Research	March 2014- June 2015
Post-Doctoral Research Associates	National Institute of Immunology, New Delhi, INDIA	Cancer Stem Cell Biology	March 2013- March 2014

  

Research Projects (Funded):

Ongoing:

1. Project Title: “Role of HOTAIRM1 long non-coding RNA in chemo resistance of acute myeloid Leukemia”. Funded by DST, Budget 48.49 Lacs [Role: As PI, Duration 3 Years, 2019-2022]
2. Project Title “Elucidation of the role of long non-coding RNA-Ginir as a biomarker in lung tumorigenesis”. Funding Agency: DBT; Duration: 03 years; Funds: 89 lakhs (In collaboration with NCCS, Pune (Role: Co-investigator)
3. Project Title “Evaluation of regulation of programmed death-ligand 1 (PD-L1) expression by microRNA in lung cancer”. Funding Agency: ICMR; Duration: 8/2019-8/2022; Funds: 47.64 lakhs (Role: Co-investigator)
4. Project Title “Study of Clinical Significance of Genetic Alterations and Feasibility of Adopting Children Oncology Group (COG) Risk-based Stratification of Wilms Tumor in Indian Children” Funding Agency: ICMR; Duration: 8/2020-8/2023 (Role: Co-P investigator)

 

Completed

1. Project Title “The clinical significance of HOTAIR and HOTAIRM1 long non-coding RNAs in paediatric acute myeloid leukaemia.” Funded By AIIMS, New Delhi, Project Code A509; Budget 8.6 lakhs (2017-2019) (Role: PI)
2. Project Title “Elucidating the mechanism of regulation of PD-L1 expression in lung cancer – role of epigenetics and copy number alterations”. Funding Agency: AIIMS; Duration: 09/2017-09/2019; Funds: 10 lakhs (Role: Co-investigator)

List of Publications  

1. Kumar S, Pandey M and Sharawat SK Biological Functions of Long Non-Coding RNAs and Circular RNAs in Small Cell Lung Cancer. Epigenomics (Accepted, Ahead of print)
2. Bansal AK, Sharawat SK, Gupta R, Vishnubhatla S, Dhawan D, Bakhshi S. Regulatory T cells in pediatric AML are associated with disease load and their serial assessment suggests role in leukemogenesis. Am J Blood Res. 2020 Aug 25;10(4):90-96. eCollection 2020. [PubMed PMID: 32923088]
3. Bhat AA, Younes SN, Raza SS, Zarif L, Nisar S, Ahmed I, Mir R, Kumar S, Sharawat SK, et al. Role of non-coding RNA networks in leukemia progression, metastasis and drug resistance. Mol Cancer. 2020 Mar 12;19(1):57. [PubMed PMID: 32164715]
4. Kumar S, Sharawat SK, Ali A, Gaur V, Malik PS, Pandey M, Kumar S, Mohan A, Guleria R. Differential expression of circulating serum miR-1249-3p, miR-3195 and miR-3692-3p in non-small cell lung cancer. Human Cell. 2020 Jul;33(3):839-849 [PubMed PMID: 32215864]
5. Kumar S, Sharawat SK, Ali A, Gaur V, Malik PS, Kumar S, Mohan A, Guleria R. Identification of differentially expressed circulating serum microRNA for the diagnosis and prognosis of Indian non-small cell lung cancer patients. Curr Probl Cancer 2020 Aug;44(4):100540. [PubMed PMID: 32007320]
6. Gaur V, Chaudhary S, Tyagi A, Agarwal S, Sharawat SK, Sarkar S, Singh H, Bakhshi S, Sharma P, Kumar S. Dysregulation of miRNA expression and their prognostic significance in pediatric cytogenetically normal acute myeloid leukemia. British J of Hematology, 2020 188: e90–e94. (IF 5.2) 145 [PubMed PMID: 32077100]
7. Baccarani M, Castagnetti F, Gugliotta G, Rosti G, Soverini S, Albeer A, Pfirrmann M, Sharawat SK, Kumar L. (for the International BCR-ABL Study Group) The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview, Leukemia 2019; 33, 1173–1183 (IF 12.03) [PubMed PMID: 30675008]
8. Kumar S and Sharawat SK. Epigenetic Regulators of PD-L1 Expression in Human Cancers. Transl Res. 2018; 202:129-145 [PubMed PMID: 30401465] (IF 4.915)
9. KumarS, Gaur V, Khurana S, Bose S, Kiran M, Sharawat SK. Proteomics – An Update on Recent Tools and Techniques. EC Proteomics and Bioinformatics 2.2 (2018): 57-73.
10.  Sharawat SK*, Akhter M Z*, Kumar V*, Kochat V, Equbal Z, Ramakrishnan M , Kumar U, Mathur S, Kumar L, Mukhopadhyay A. Aggressive serous epithelial ovarian cancer is potentially propagated by EpCAM+CD45+ phenotype. Oncogene; 2018 Apr;37(16):2089-2103. [PubMed PMID: 29379166] *Contributed Equally
11. Sharawat SK, Vishnubhatla S, Bakhshi R, Raina V,Kumar L,Sharma A,Bakhshi S. High fms-like tyrosine kinase-3 (FLT3) receptor surface expression predicts poor outcome in FLT3 internal tandem duplication (ITD) negative patients in adult acute myeloid leukaemia: a prospective pilot study from India. Indian J Med Res. 2016 May;143 (Supplement): S11-S16. [PubMed PMID: 27748272]
12. Sharawat SK, Vishnubhatla S, Bakhshi R, Raina V,Kumar L,Sharma A,Bakhshi S.Relative Receptor Tyrosine Kinases and Anti-Apoptotic Transcripts Hold Potential for Predicting Inferior Outcome in Adult Acute Myeloid Leukemia: A Prospective Pilot Study. Blood Cells Mol Dis. 2015 Jan;54(1):56-64[PubMed ID: 22420668]
13. Kesherwani V, Nandi SS, Sharawat SK, Shahshahan HR and Mishra PK. Hydrogen sulfide mitigates homocysteine-mediated pathological remodeling by inducing miR-133a in cardiomyocytes. Mol Cell Biochem. 2015 Jun;404(1-2):241-50 [PubMed ID: 25763715]
14. Sharawat SK,Bakhshi R, Vishnubhatla S,  Gupta R,Bakhshi S. FLT3-ITD Mutation in Relation to FLT3 Expression in Pediatric AML: a Prospective Study from India. Pediatr Hematol Oncol. 2014 Mar;31(2):131-7 [PMID: 24498869]
15. Sharawat SK, Raina V,Kumar L,Sharma A,Bakhshi R, Vishnubhatla S, Gupta R, Bakhshi S. Prospective Evaluation of Significance of Transcript and Flow-cytometric Expression of Bax in Acute Myeloid Leukemia. Hematology. 2014 Jan 3. [PMID:24620954]
16. Tilak TVSVGK, Sharawat SK, Gupta R, Agarwala S, Vishnubhatla S, Bakhshi S, Circulating T-Regulatory Cells in Neuroblastoma: a Pilot Prospective Study. PediatrHematolOncol. 2014 Mar 31 [PMID: 24684178]
17. Sharawat SK, Radhika Bakhshi, Vishnubhatla S, Gupta R, Bakhshi S.  Bax/Bcl2 RMFI Ratio Predicts Better Induction Response in Pediatric Acute Myeloid Leukemia. Pediatric Blood and Cancer 2013 Aug; 60(8):E63-6 [PubMed ID: 23553948]
18. Tilak TVSVGK, Sharawat SK , Gupta R, Agarwala S, Vishnubhatla S, Bakhshi S, Circulating T-Regulatory Cells in PNET: a Prospective Study. Pediatric Blood and Cancer, 2013 [PubMed ID: 23997029]
19. Sharawat SK , Gupta R, Raina V,Kumar L,Sharma A,Iqbal S, Bakhshi R, Vishnubhatla S, Bakhshi S. Increased Co-Expression of c-KIT and FLT-3 Receptors on Myeloblasts: Independent Predictor of Poor Outcome in Acute Myeloid Leukemia. Cytometry B Clinical Cytometry 2013 [PubMed ID: 23740774]
20. Sharawat SK, Vishnubhatla S, Bakhshi R, Raina V,Kumar L,Sharma A,Bakhshi S. Relative Receptor Tyrosine Kinases and Anti-apoptotic Transcripts Hold Potential for Predicting Inferior Outcome in Adult Acute Myeloid Leukemia: A Prospective Pilot Study.Clin Lymphoma Myeloma Leuk 2013[PMID: 25065779]
21. Mandhaniya S, Iqbal S, Sharawat SK, Xess I, Bakhshi S. Diagnosis of invasive fungal infections using real-time PCR assay in paediatric acute leukaemia induction. Mycoses. 2012 Jul; 55(4):372-9 [PubMed ID: 22420668].
22. Gogia A, Sharawat SK, Kumar R, Sarkar C, Bakhshi S. Systemic Mastocytosis Associated With Childhood Acute Myeloid Leukemia. J PediatrHematolOncol. 2012 May 10 [PubMed ID: 22584780].
23. Sharawat SK,Bakhshi R, Vishnubhatla S, Bakhshi S. Mitochondrial D-loop variations in paediatric acute myeloid leukaemia: a potential prognostic marker. Br J Haematol. 2010 May; 149(3):391-8. Epub 2010 Mar 8 [PubMed ID: 20230407].
24. Gupta N, Gupta R, Sharawat SK, Bakhshi S. Childhood chronic myeloid leukemia with monocytosis. Indian J Pediatr. 2010 Oct; 77 (10):1143-5. Epub 2010 Sep 30 [PubMed ID: 20882436].

 

Abstracts Published:  

1. Sharma D, Bhardwaj T , Chaitanya , Kumar S , Bakhshi S , Sharawat SK*. Expression of UCA1 long noncoding RNA in Pediatric Acute Myeloid Leukemia. Jan 2020, RGCON New Delhi
2. Kumar S, Sharawat SK, Ali A, Malik P, Mohan A, Guleria R.  Diagnostic and Prognostic Utility of Differentially Expressed Circulating MicroRNAs in Indian NSCLC Patients. Journal of Thoracic Oncology 14 (10), S960-S961: 2019
3. Sharawat SK, Gupta R, Vishnubhatla S, Raina V, Kumar L, Sharma A, Bakhshi R, Iqbal S, Bakhshi S High Co-expression of CD135 and CD117 Predicts Poor Outcome in Acute Myeloid Leukemia: a Prospective Study. Annl Oncl, 2012: 23; 349-9.
4. Sharawat SK, Bakhshi S, Gupta R, Vishnubhatla S, Bakhshi R. Proliferative and anti-apoptotic transcript ratio predicts outcome in pediatric acute myeloid leukemia. Pediatr Blood Cancer: 2012; DOI 10.1002/pbc
5. Sharawat SK, Bakhshi S, Gupta R, Iqbal S, Vishnubhatla S, Bakhshi R. Increased co-expression of CD135 and CD117 predicts outcome in pediatric acute myeloid leukemia: a prospective study Pediatr Blood Cancer: 2012; DOI 10.1002/pbc
6. Sharawat SK, Nandi SS, Kesherwani V, Shahshahan HR, Mishra PK. Mdivi-1 Mitigates ROS and Mitophagy, Improves Healthy Mitochondrial Pool in Hyperglycemic Cardiomyocytes., FASEB (2015), 29;1(S);1040.4
7. Mandhaniya S., Iqbal S., Sharawat SK, Xess I., Bakhshi S.. Diagnosis of invasive fungal infections by RQ-PCR assay in pediatric acute leukemia induction. J Clin Oncol 2010, 28:15s, 9579.
8. Tilak Tvsvgk, Sharawat SK, Gupta R, Agarwala S, Khan SA, Rastogi S, Vishnubhatla S, Bakhshi S.Assessment of peripheral blood T regulatory cells (Tregs) in PNET/Ewing sarcoma: A prospective study. J Clin Oncol, 2012; 30S: 9580).
9. Bakhshi S, Bansal AK, Sharawat SK, Gupta R, Vishnubhatla S. Serial assessment of humoral immunity in pediatric AML: A prospective study. J Clin Oncol, 2012; 30S:9551
10. Bansal AK, Sharawat SK, Gupta R, Vishnubhatla S, Bakhshi S. Serial assessment of regulatory T cells (Tregs) in pediatric AML: A prospective study. J Clin Oncol, 2012: 30S:9549.
11. Tilak Tvsvgk, Sharawat SK, Gupta R, Agarwala S, , Vishnubhatla S, Bakhshi S. Assessment of kinetics of peripheral blood t regulatory cells (tregs) in neuroblastoma: a prospective study. Pediatr Blood Cancer: 2012; DOI 10.1002/pbc
12. Bansal AK, Sharawat SK, Gupta R, Vishnubhatla S, Bakhshi S. Correlation of serum immunoglobulins, B cells, T cells and natural killer cells with infection-related parameters during induction chemotherapy of pediatric acute myeloid. Pediatr Blood Cancer: 2012; DOI 10.1002/pbc

 

* As Corresponding Author

 

Academic Responsibilities:     

• Scientist In charge, Leukemia Cytogenetic Services, Department of Medical Oncology. Dr. B. R. Ambedkar IRCH. AIIMS New DelhiInvolvement in academic teaching schedules of graduates and postgraduates (DM/ M.Tech/M.Sc./B.Tech/ B.Sc.)
• Teaching credentials [Stem cell technology, Bio Medical Engineering, Biochemistry, Immunology, Cell Biology, Recombinant DNA Technology (RDT)]
• Mentorship for dissertations of graduate and postgraduate students in AIIMS summer research training module.
• International conference (Active participation):
• PhD Research work was presented and discussion by ESMO panellist in ESMO Congress 2012, Vienna Austria.

Membership of Scientific Bodies

• ASA: AIIMS Scientist Association- First Elected President (2019-2022)

• RESMO: Research and education society of Medical Oncology,

• Dr B.  R.  Ambedkar, IRCH AIIMS, New Delhi-Founder Member-2019

• ASMO: American Society of Medical ONCOLOGY: 2012-13

• ESMO: European Society of Medical Oncology-2012-2013

• IACR: Indian association of cancer research - Life Member  

Educational Awards:  

• Qualified National Eligibility Test (NET) conducted by Council for Scientific and Industrial Research (CSIR) and University Grant Commission (UGC) of INDIA in June 2005
• Qualified Indian council of Medical Research (ICMR) examination for Junior Research Fellowship in July 2005
• Qualified Indian council of Medical Research (ICMR) examination for Junior Research Fellowship in July 2006  (1st February 2007 to 31 January 2009)
• Awarded Senior research fellowfrom Indian council of Medical Research (ICMR) from 1st February 2009 to August 2012
• Awarded Institute Fellowship grant (AIIMS) form 1st February 2012 to 31October, 2012
• Young Investigator Travel Award by European Society of Medical Oncology (ESMO) 2012 in Vienna Austria.
• First Prize for best oral presentation award by society of young scientist (SYS) 2012, AIIMS, New Delhi.
• Early career research Award (Serb-DST): 2019, Ministry of Science and Technology, Government of India New Delhi